The Immune Circuit Hidden in Your Gut Wall That Could Revolutionize IBD Treatment

For decades, eosinophils were treated as minor players in gut inflammation, cells that showed up during IBD flares and remission alike without anyone being sure why. A new study published in PNAS flips that assumption: eosinophil-derived COX-2 turns out to anchor a protective immune relay that bolsters the intestinal barrier and limits colitis severity. The findings are preliminary, drawn from mouse models, but they open a mechanistic door that current IBD therapies have largely ignored.

How Eosinophil COX-2 Drives IL-22 Production in Colitis

The core discovery centers on cyclooxygenase-2 (COX-2, gene name Ptgs2), an enzyme best known for its role in inflammation and as the target of NSAIDs like ibuprofen. RNA-sequencing of colonic eosinophils isolated from dextran sulfate sodium (DSS)-treated mice showed COX-2 was significantly upregulated during colitis. To test what that upregulation actually does, the team generated mice with an eosinophil-specific deletion of COX-2 (Ptgs2 fl/fl eoCre +/-).

The result was striking. Without eosinophil COX-2, colonic prostaglandin E2 (PGE2) levels dropped, and production of interleukin-22 (IL-22) fell with it. IL-22 is a cytokine that directly signals epithelial cells to reinforce the gut lining; defects in the intestinal epithelial barrier are a defining feature of IBD, affecting mucus production, tight junction integrity, and antimicrobial peptide output. When IL-22 dried up in the COX-2 knockout animals, the mice developed measurably worse colitis: greater weight loss, higher disease activity scores, shortened colons, and more extensive epithelial injury than control animals exposed to the same DSS challenge.

Administering recombinant IL-22 directly reversed those exacerbated phenotypes, confirming that the deficit in IL-22, not some other downstream effect of losing COX-2, was driving the damage.

The PGE2-ILC3 Signaling Axis at the Center of Gut Barrier Defense

The mechanistic chain runs through a second immune cell type: type 3 innate lymphoid cells (ILC3s). Innate lymphoid cells are tissue-resident immune sentinels that respond rapidly to local signals without requiring antigen-specific activation. The study shows that PGE2 produced by eosinophil COX-2 signals to ILC3s via the EP4 receptor, prompting those cells to ramp up IL-22 secretion.

Previous work has shown that ILC2s, a related innate lymphoid cell type, promote intestinal barrier integrity during type 2 immune responses; the new findings extend that principle to ILC3s in the context of active colitis. When the researchers treated COX-2 knockout mice with a PGE2 analog, IL-22 production recovered and mucosal protection was restored, completing the circuit: eosinophil COX-2 makes PGE2, PGE2 activates ILC3s through EP4, ILC3s release IL-22, and IL-22 shields the epithelium.

Yingzi Cong, PhD, a lead researcher on the study, described the broader logic plainly: "In the experimental models and context of our studies, it appears that eosinophils help to restrain or limit the inflammatory response in the colon by generating signaling molecules that impact other immune cells to turn down the inflammatory response."

Why IBD Patients Urgently Need Barrier-Targeted Treatments

Around 2.4 to 3.1 million people in the United States are estimated to live with IBD, and both prevalence and healthcare costs continue to climb. Current therapies focus predominantly on suppressing immune activity, using biologics that block TNF-alpha, integrins, or IL-12/23 signaling. Those drugs help many patients, but a substantial share do not respond to initial treatment, and secondary loss of response is common, leaving clinicians cycling through options without addressing the underlying barrier dysfunction.

When the gut lining breaks down in IBD, luminal bacteria translocate into the mucosa and activate immune cells, perpetuating the inflammatory cycle. Strengthening that barrier, rather than only dampening the immune response, is increasingly seen as a distinct and necessary therapeutic goal. As Cong put it: "This may help to improve treatment strategies for IBD by providing a new target: medications or techniques to augment this protective circuit may strengthen the intestinal barrier and protect against the development or progression of inflammation in IBD."

Limitations of the Mouse Models Used

The study's findings are compelling within their scope, but the primary evidence comes from DSS- and TNBS-induced colitis in mice, which are standard preclinical models but imperfect proxies for human Crohn's disease or ulcerative colitis. The authors acknowledge that broader consequences of impaired barrier defense, including systemic inflammation, were noted but not the central focus of the work.

The PGE2/EP4-ILC3-IL-22 axis does appear in human biology as well; the paper notes that this axis is downregulated in human systemic inflammatory disease, suggesting the mouse findings may translate. But direct human data are absent from this study, and the specific factors that regulate the eosinophil-ILC3 circuit's activity remain to be identified.

The Next Steps for This Eosinophil-ILC3 Research

The immediate research agenda, according to the team, involves identifying the precise signals that promote or suppress this eosinophil-COX-2-PGE2-ILC3-IL-22 circuit in human IBD tissue. That mechanistic map would be necessary before any drug development could begin in earnest.

On the therapeutic side, emerging strategies for ulcerative colitis already include tight junction stabilization, epithelial regeneration, and MUC2 mucus layer restoration as candidates. The eosinophil COX-2 circuit would slot into that same barrier-repair framework, potentially as a target for small molecules or biologics that amplify PGE2 signaling to ILC3s without the systemic side effects of broad COX-2 inhibitors like NSAIDs. That distinction matters: NSAIDs block COX-2 everywhere and can worsen gut inflammation in some IBD patients, which makes eosinophil-specific or ILC3-targeted approaches conceptually appealing even at this early stage. Whether those approaches survive translation to human trials is a question the next phase of research will have to answer.

Evidence rating

INVESTIGATIONAL — 78/100

Caveats:

• This study was conducted entirely in mouse models of colitis (DSS and TNBS); findings have not yet been tested in human clinical trials.
• The causal mechanism is well-mapped in mice, but whether the same eosinophil–PGE2–ILC3–IL-22 axis operates identically in human IBD remains to be confirmed.
• Funding was not disclosed by the authors, so independent verification of financial interests cannot be confirmed.

Preclinical mouse study using genetic knockout models and two chemically induced colitis systems (DSS and TNBS). Demonstrates a detailed mechanistic causal chain — eosinophil COX-2 → PGE2 → ILC3 → IL-22 → barrier protection — but all findings are in animals and have not been replicated in independent mouse cohorts or translated to human subjects. Funding was not declared by the authors.

References

1. Yang Yang, Constance L. Atkins, Yuanyuan Fan, et al. (2026). Eosinophil-derived COX-2 protects against experimental colitis through the PGE ₂ –IL-22 axis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2525334123
2. Intestinal barrier in inflammatory bowel disease – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838491/
3. Philip B. Kidd, Michael W. Young, Eric D. Siggia (2015). Temperature compensation and temperature sensation in the circadian clock. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1511215112
4. IBD Facts and Stats – CDC. cdc.gov. https://www.cdc.gov/ibd/data-statistics/facts-stats.htm
5. Mohamed Mahmoud Hafez, Ibrahim Halil Bahcecioglu, Mehmet Yalniz, Karim Abdelwahab Kouta, Ahmed Tawheed (2025). Future of inflammatory bowel disease treatment: A review of novel treatments beyond guidelines. World Journal of Methodology. https://doi.org/10.5662/wjm.v15.i4.107643
6. Mei-Na Wang, Chuan-Guo Liu, Jia Pan, Xiao-Gang Pang, Hui-Min Liu (2026). Intestinal Barrier: Mechanisms of Disruption and Strategies for Restoration in Ulcerative Colitis. https://doi.org/10.20944/preprints202604.0397.v1